Search alternatives:
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
larger decrease » marked decrease (Expand Search)
teer decrease » mean decrease (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
larger decrease » marked decrease (Expand Search)
teer decrease » mean decrease (Expand Search)
-
541
Measurements of the amount of ATP released by bladder distention and VNUT expression in the bladder.
Published 2024Subjects: -
542
-
543
KO of iPLA<sub>2</sub>γ attenuates development of albuminuria in STZ-induced diabetic nephropathy.
Published 2024Subjects: -
544
-
545
Control (Ctrl) GECs are more susceptible to injury compared to iPLA<sub>2</sub>γ KO GECs.
Published 2024Subjects: -
546
-
547
Podocyte numbers in control and iPLA<sub>2</sub>γ KO mice (WT1-positive cells).
Published 2024Subjects: -
548
-
549
-
550
Presentation 1_Ceftriaxone-associated dysbiosis decreases voriconazole bioavailability by upregulating intestinal P-glycoprotein expression through activation of the Nrf2-mediated...
Published 2025“…</p>Key findings<p>The diversity and richness of intestinal bacteria, especially the abundance of gram-negative bacteria, were significantly decreased after ceftriaxone treatment. …”
-
551
Table 1_Ceftriaxone-associated dysbiosis decreases voriconazole bioavailability by upregulating intestinal P-glycoprotein expression through activation of the Nrf2-mediated signall...
Published 2025“…</p>Key findings<p>The diversity and richness of intestinal bacteria, especially the abundance of gram-negative bacteria, were significantly decreased after ceftriaxone treatment. …”
-
552
Changes in best-corrected visual acuity and total area reduction ratio of the epiretinal membrane (ERM) during follow-up.
Published 2025“…<p>(a) During the follow-up period, the stable group showed no significant change in visual acuity, whereas the progression group exhibited a decrease compared to baseline starting at 12 months, with greater changes than those in the stable group beginning at 6 months. …”
-
553
Data.
Published 2025“…Participants in the progression group were younger (60.7 vs. 65.7 years, P = 0.015) and showed a larger BCVA change (0.20 vs. 0.04, P < 0.001) and greater ERM area decrease (34.2% vs. 11.7%, P < 0.001) during the follow-up period. …”
-
554
Baseline characteristics of patients.
Published 2025“…Participants in the progression group were younger (60.7 vs. 65.7 years, P = 0.015) and showed a larger BCVA change (0.20 vs. 0.04, P < 0.001) and greater ERM area decrease (34.2% vs. 11.7%, P < 0.001) during the follow-up period. …”
-
555
-
556
Advantages of Novel Anti-cancer Selenosemicarbazones: Preferential Reactivity of Their Fe(III), Cu(II), and Zn(II) Complexes with Key Physiological Reductants/Ligands Versus Isoste...
Published 2025“…The role of glutathione in all three latter reactions is significant, given the greater reactivity of the selenosemicarbazone, and glutathione’s key role in selenosemicarbazone and thiosemicarbazone anticancer activity.…”
-
557
Advantages of Novel Anti-cancer Selenosemicarbazones: Preferential Reactivity of Their Fe(III), Cu(II), and Zn(II) Complexes with Key Physiological Reductants/Ligands Versus Isoste...
Published 2025“…The role of glutathione in all three latter reactions is significant, given the greater reactivity of the selenosemicarbazone, and glutathione’s key role in selenosemicarbazone and thiosemicarbazone anticancer activity.…”
-
558
-
559
-
560